Epistasis as a Determinant of the HIV-1 Protease's Robustness to Mutation

被引:1
|
作者
Capel, Elena
Parera, Mariona
Angel Martinez, Miguel [1 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Fundacio IrsiCaixa, Badalona, Spain
来源
PLOS ONE | 2014年 / 9卷 / 12期
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; DELETERIOUS MUTATIONS; REVERSE-TRANSCRIPTASE; REPLICATION CAPACITY; CATALYTIC EFFICIENCY; GENETIC ROBUSTNESS; FITNESS LANDSCAPE; IN-VITRO; EVOLUTION; PROTEIN;
D O I
10.1371/journal.pone.0116301
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The robustness of phenotypes to mutation is critical to protein evolution; robustness may be an adaptive trait if it promotes evolution. We hypothesised that native proteins subjected to natural selection in vivo should be more robust than proteins generated in vitro in the absence of natural selection. We compared the mutational robustness of two human immunodeficiency virus type 1 (HIV-1) proteases with comparable catalytic efficiencies, one isolated from an infected individual and the second generated in vitro via random mutagenesis. Single mutations in the protease (82 and 60 in the wild-type and mutant backgrounds, respectively) were randomly generated in vitro and the catalytic efficiency of each mutant was determined. No differences were observed between these two protease variants when lethal, neutral, and deleterious mutations were compared (P=0.8025, chi-squared test). Similarly, average catalytic efficiency (-72.6% and -64.5%, respectively) did not significantly differ between protease mutant libraries (P=0.3414, Mann Whitney test). Overall, the two parental proteins displayed similar mutational robustness. Importantly, strong and widespread epistatic interactions were observed when the effect of the same mutation was compared in both proteases, suggesting that epistasis can be a key determinant of the robustness displayed by the in vitro generated protease.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] DIMERIZATION INHIBITORS OF HIV-1 PROTEASE
    CHMIELEWSKI, J
    FRANCISKOVICH, J
    WILSON, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 138 - ORGN
  • [32] A folding inhibitor of the HIV-1 protease
    Broglia, RA
    Provasi, D
    Vasile, F
    Ottolina, G
    Longhi, R
    Tiana, G
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2006, 62 (04) : 928 - 933
  • [33] HIV-1 protease inhibitors: A review
    Dietrich, MA
    Butts, JD
    Raasch, RH
    INFECTIONS IN MEDICINE, 1999, 16 (11) : 716 - +
  • [34] Novel HIV-1 protease inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (12) : 533 - 534
  • [35] Adaptive inhibitors of the HIV-1 protease
    Ohtaka, H
    Freire, E
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2005, 88 (02): : 193 - 208
  • [36] Heterocyclic HIV-1 protease inhibitors
    Baures, PW
    ORGANIC LETTERS, 1999, 1 (02) : 249 - 252
  • [37] Lipopeptides as inhibitors of HIV-1 protease
    Schramm, HJ
    Büttner, J
    de Rosny, E
    Reboud-Ravaux, M
    Dick, A
    Schramm, W
    AIDS, 1998, 12 : S77 - S77
  • [38] Folded monomer of HIV-1 protease
    Ishima, R
    Ghirlando, R
    Tözsér, J
    Gronenborn, AM
    Torchia, DA
    Louis, JM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) : 49110 - 49116
  • [39] HIV-1 protease and its inhibitors
    Geller, M
    Trylska, J
    Antosiewicz, J
    THEORETICAL AND COMPUTATIONAL METHODS IN GENOME RESEARCH, 1997, : 237 - 254
  • [40] AZIRIDINE INHIBITORS OF HIV-1 PROTEASE
    LEVERETT, B
    BAI, JC
    POST, CB
    LOUDON, GM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 37 - MEDI